Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.6296
-0.0144 (-2.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.6025
-0.0271 (-4.30%)
After-hours: Dec 5, 2025, 7:56 PM EST
Virax Biolabs Group Revenue
Virax Biolabs Group had revenue of $1.61K in the half year ending September 30, 2025, a decrease of -97.90%. This brings the company's revenue in the last twelve months to $2.99K, down -96.48% year-over-year. In the fiscal year ending March 31, 2025, Virax Biolabs Group had annual revenue of $6.33K, down -95.95%.
Revenue (ttm)
$2.99K
Revenue Growth
-96.48%
P/S Ratio
1,379.69
Revenue / Employee
$157
Employees
19
Market Cap
4.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VRAX News
- 2 days ago - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PRNewsWire
- 3 days ago - Virax Biolabs Group Limited Announces $5 Million Private Placement - PRNewsWire
- 3 days ago - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PRNewsWire
- 4 weeks ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
- 3 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
- 4 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
- 5 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
- 8 months ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga